Protalix BioTherapeutics (NYSE:PLX - Get Free Report) was downgraded by StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Monday.
Separately, HC Wainwright increased their price objective on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd.
Get Our Latest Report on Protalix BioTherapeutics
Protalix BioTherapeutics Stock Performance
PLX stock remained flat at $1.67 during trading on Monday. 655,592 shares of the company traded hands, compared to its average volume of 527,703. Protalix BioTherapeutics has a one year low of $0.82 and a one year high of $3.10. The stock has a 50-day simple moving average of $2.49 and a 200 day simple moving average of $2.15. The stock has a market capitalization of $132.94 million, a PE ratio of -12.85 and a beta of -0.05.
Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative return on equity of 30.89%. As a group, equities research analysts anticipate that Protalix BioTherapeutics will post 0.01 EPS for the current fiscal year.
Institutional Trading of Protalix BioTherapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC boosted its position in Protalix BioTherapeutics by 82.1% in the first quarter. Cubist Systematic Strategies LLC now owns 53,380 shares of the company's stock valued at $137,000 after buying an additional 24,073 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Protalix BioTherapeutics in the 1st quarter valued at $459,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Protalix BioTherapeutics during the 1st quarter worth $1,236,000. XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics during the 1st quarter worth $107,000. Finally, Stratos Wealth Partners LTD. lifted its stake in Protalix BioTherapeutics by 28.3% during the 1st quarter. Stratos Wealth Partners LTD. now owns 346,400 shares of the company's stock worth $887,000 after acquiring an additional 76,400 shares in the last quarter. 16.53% of the stock is currently owned by institutional investors.
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Featured Articles
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
